Drugs / PDA001
PDA001
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03797040 | Jan → Dec 2021 | drug or radiation exposure-related interstitial lung disease | Pluristem Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03002519 | Feb 2017 → Sep 2021 | disease related to hematopoietic stem cell transplant | Pluristem Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01769755 | Mar 2013 → Nov 2014 | Crohn disease | Celularity Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01440192 | Sep 2011 → Feb 2014 | pulmonary sarcoidosis | Celularity Incorporated | Terminated | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT01310114 | Mar 2011 → Mar 2013 | middle cerebral artery infarction, posterior cerebral artery infarction | Celularity Incorporated | Terminated | No outcome recorded |
| Phase 2 | NCT01261403 | Dec 2010 → Feb 2012 | rheumatoid arthritis | Celularity Incorporated | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01155362 | Aug 2010 → Feb 2012 | Crohn disease | Celularity Incorporated | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Celularity Incorporated | Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies celularity.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDA-001 | “PDA-001 (cenplacel-L), a preparation of placenta-derived mesenchymal-like adherent cells with immunomodulatory effects, previously demonstrated safety and tolerability in an...” PMID 25985246 ↗ Aug 2015 |
| Known as | cenplacel-L | “PDA-001 (cenplacel-L), a preparation of placenta-derived mesenchymal-like adherent cells with immunomodulatory effects, previously demonstrated safety and tolerability in an...” PMID 25985246 ↗ Aug 20152“Human Placenta-Derived Cells PDA001- (cenplacel-L)” NCT01310114 ↗ “PDA001 (cenplacel-L)” NCT01440192 ↗ |
| Known as | PLX-R18 | “PLX-R18: Allogeneic ex vivo expanded placental stromal cells” NCT03797040 ↗ |
| Modality | Cell therapy | “a preparation of placenta-derived mesenchymal-like adherent cells” PMID 25985246 ↗ Aug 2015 |
| Route | Intravenous | “PDA001 administered intravenously” NCT01155362 ↗ |